Skip to content

Role of Neuronal Guidance Proteins as Diagnostic Markers for Acute Kidney Injury (AKI)

Role of Neuronal Guidance Proteins as Diagnostic Markers for Acute Kidney Injury (AKI)

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05924269
Acronym
NEUKID
Enrollment
600
Registered
2023-06-29
Start date
2023-08-31
Completion date
2026-07-31
Last updated
2023-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Keywords

Neuronal Guidance Protein, Acute Kidney Injury

Brief summary

Acute kidney failure remains one of the most challenging entities to diagnose in clinical medicine, especially in the field of intensive care. The diagnosis of acute kidney injury is based solely on urine output and serum creatinine, both of which could also be influenced by other factors. A more sensitive and faster diagnostic option would not only be desirable but of utmost clinical importance. Therefore, the investigators aim to identify Neuronal Guidance Proteins (NGPs) as potential biomarkers for the identification and early detection of AKI with this investigation. This investigation aims to identify the possibility of diagnosing acute kidney injury, the subsequent validation of a potential biomarker will then have to take place in a multicenter study approach: Data in preclinical mouse models suggest that SEMA7A as one of the NGPs could be valuable as a biomarker, the study now aims to attempt a preliminary survey in humans and measure various NGPs.

Interventions

None listed

Sponsors

University Hospital Tuebingen
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Patients undergoing cardiac surgery * written consent

Exclusion criteria

* no written consent possible * Polytrauma, severe burns * Immunosuppression * Pregnancy * Diagnosis of Hepatitis B, Hepatitis C, and/or HIV * Sepsis * Pre-existing kidney damage

Design outcomes

Primary

MeasureTime frameDescription
AKI1-7 daysDevelopment of AKI after cardiac surgery

Secondary

MeasureTime frameDescription
NGP1-7 daysConcentration of NGPs in Blood and Urine

Contacts

Primary ContactAndreas Körner, MD
andreas.koerner@med.uni-tuebingen.de+497071-29 61783
Backup ContactMichael Koeppen, MD
michael.koeppen@med.uni-tuebingen.de+497071-29 86935

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026